ArticleScientific reports2025
Machine learning-assisted multi-dimensional transcriptomic analysis of cytoskeleton-related molecules and their relationship with prognosis in hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, with a poor prognosis due to its aggressive nature and limited treatment options. Cytoskeletal dynamics play a critical role in tumor progression, but the prognostic and therapeutic potential of cytoskeleton-related genes in HCC remains underexplored. In this study, transcriptomic data from the TCGA-LIHC dataset were used to identify differentially expressed cytoskeleton-related genes associated with overall survival (OS). Prognostic models were constructed using LASSO regression and random forest algorithms, and validated in two independent cohorts (ICGC LIRI-JP and CHCC-HBV). Single-cell sequencing (scRNA-seq) and spatial transcriptomics analyses explored the expression and functional roles of key genes, while drug screening and molecular docking identified potential therapeutic agents, followed by in vitro and in vivo validation. The analysis identified 110 cytoskeleton-related DEGs, with 13 significantly associated with OS. A robust five-gene prognostic model (ARPC1A, CCNB2, CKAP5, DCTN2, TTK) was developed using LASSO regression and validated across cohorts. The model was integrated into a clinical nomogram, demonstrating good calibration and utility. Single-cell and spatial transcriptomics revealed high expression of the five genes in malignant tissues and their association with immunosuppressive microenvironments. High-risk scores correlated with TP53 mutations. Drug screening identified irinotecan and sorafenib as potential agents targeting TTK, with combined treatment significantly inhibiting tumor growth in vitro and in vivo. This study highlights the prognostic and therapeutic significance of cytoskeleton-related genes in HCC. The five-gene model provides a reliable tool for risk stratification, and the irinotecan-sorafenib combination shows promise as a therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.